Brief: Urogen Pharma Posts Q4 Loss Per Share Of $1.86

UroGen Pharma

02/03/2020 13:46

March 2 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2019
FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS
    * Q4 LOSS PER SHARE $1.86
    * PRESCRIPTION DRUG USER FEE ACT GOAL DATE OF APRIL 18(TH
    * EXPERIENCED COMMERCIAL TEAM HIRED AND PREPARED FOR PLANNED
UGN-101 APPROVAL AND LAUNCH IN Q2
    * ANTICIPATES OPERATING EXPENSES IN RANGE OF $145 TO $155
MILLION
FOR 2020
    * NON-CASH STOCK-BASED COMPENSATION EXPENSE FOR 2020 IS
EXPECTED
TO BE IN RANGE OF $32 TO $36 MILLION
    * OTHER NON-OPERATING INCOME FOR 2020 IS ANTICIPATED TO BE
APPROXIMATELY $2.5 MILLION
    * QTRLY LOSS PER SHARE $1.86
    * Q4 EARNINGS PER SHARE VIEW $-1.70 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw1c6Ll4a 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))